Page last updated: 2024-12-08
mt-81 toxin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
MT-81 toxin: isolated from Penicillium nigricans; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 146437 |
MeSH ID | M0136765 |
Synonyms (20)
Synonym |
---|
mt-81 toxin |
mt 81 |
9,10-anthracenedione, 1,5-dihydroxy-3-methyl-8-((2,6,7,7a-tetrahydro-4h-furo(3,2-c)pyran-4-yl)oxy)- |
brn 4596898 |
mycotoxin mt 81 |
mt81 mycotoxin |
mycotoxin 81 |
1,5-dihydroxy-3-methyl-8-((2,6,7,7a-tetrahydro-4h-furo(3,2c)pyran-4-yl)oxy)-9,10-anthracenedione |
mycotoxin mt81 |
93513-59-8 |
TUSQXSZBOGDCBU-UHFFFAOYSA-N |
1,5-dihydroxy-3-methyl-8-[(2,6,7,7a-tetrahydro-4h-furo[3,2-c]pyran-4-yl)oxy]-9,10-anthracenedione |
8-(2,6,7,7a-tetrahydro-4h-furo[3,2-c]pyran-4-yloxy)-1,5-dihydroxy-3-methylanthra-9,10-quinone # |
9,10-anthracenedione, 1,5-dihydroxy-3-methyl-8-((2,6,7,7a-tetrahydro-4 h-furo(3,2-c)pyran-4-yl)oxy)- |
mt8-1 |
DTXSID60918359 |
Q15425816 |
mt81 |
mycotoxin 81; mycotoxin mt 81 |
9,10-anthracenedione, 1,5-dihydroxy-3-methyl-8-[(2,6,7,7a-tetrahydro-4h-furo[3,2-c]pyran-4-yl)oxy]- |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (9)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 2 (22.22) | 18.7374 |
1990's | 4 (44.44) | 18.2507 |
2000's | 1 (11.11) | 29.6817 |
2010's | 2 (22.22) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.37
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.37) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 10 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |